A Comprehensive Review

  • P. R. Lichtlen
  • A. Reale

Table of contents

  1. Front Matter
    Pages I-XVI
  2. Adalat: Historical Aspects from the Cardiologist’s View

  3. The History of Nifedipine in Japan

  4. History of Adalat

    1. Front Matter
      Pages 7-7
    2. S. Kazda
      Pages 9-26
    3. P. D. Henry
      Pages 27-31
    4. F.-J. Bohle, G. Wiech
      Pages 33-38
    5. P. G. Hugenholtz, C. van Halem, F. J. van Dalen, M. van den Brand
      Pages 39-54
  5. Fundamentals of Adalat

    1. Front Matter
      Pages 55-56
  6. Lectures

    1. Front Matter
      Pages 73-73
    2. Hypertension

      1. I.-W. Franz, R. Ketelhut, U. Behr, U. Tönnesmann
        Pages 83-95
      2. J. B. Pevahouse, N. D. Markandu, F. P. Cappuccio, M. G. Buckley, G. A. Sagnella, G. A. MacGregor
        Pages 103-112
      3. J. H. Fuller
        Pages 113-116
      4. M. Fujishima, K. Ueda, Y. Hasuo, Y. Kiyohara, I. Abe
        Pages 117-126
    3. Coronary Heart Disease

      1. W. G. Nayler, Xin Hua Gu, M. J. Daly, S. L. Brittnell
        Pages 129-138
      2. D. Tzivoni, J. Benhorin, A. Gavish, S. Stern
        Pages 139-144
    4. Coronary Atherosclerosis

      1. A. Faggiotto
        Pages 169-179
      2. P. R. Lichtlen, W. Rafflenbeul, P. Nikutta, S. Jost, B. Wiese, INTACT Study Group
        Pages 203-221
  7. Outlook

    1. Front Matter
      Pages 232-232
    2. W. G. Nayler
      Pages 225-231
  8. Back Matter
    Pages 233-238

About these proceedings


As little as 30 years ago, cardiovascular research at Bayer was just a small sideline with in an environment dominated by chemotherapy research, and only 15 years ago, Bayer's pharmaceutical business was confined to European and Latin Ameri­ can countries, with sales in cardiovascular pharmaceuticals close to zero. It goes without saying that Adalat has changed the company as a whole in its research, development, and marketing, both in Germany and, most importantly, world­ wide. In research and development, Adalat has led the way in to new areas such as hypertension, acute neurology, dementia, atherosclerosis, and heart failure. In pharmacology, Adalat was present at the dawning of the second phar­ macological revolution, which started out from whole animal models and progres­ sed, via in vitro screening and pharmacological research on the DHP receptor, down to the molecular level with the cloning of calcium-channel proteins. Having followed the Adalat story closely in its early years as a bench scientist, let me take this opportunity to thank the inventors, the scientists, and the investigators who have helped to tap the broad potential of calcium-channel blockade with dihyd­ ropyridines in general and Adalat in particular. But, success should not obscure our vision. There is no reason for us to rest on our laurels: it will take true innovations in cardiovascular research to top the gold standard set by Adalat. Let us take up the challenge.


Dementia Kalziumantagonist Kalziumblocker angina pectoris artery atherosclerosis blood pressure cardiovascular coronary artery disease coronary heart disease heart heart disease heart failure hypertension vascular disease

Editors and affiliations

  • P. R. Lichtlen
    • 1
  • A. Reale
    • 2
  1. 1.Abtl. Innere Medizin/KardiologieMedizinische Hochschule HannoverHannover 61Germany
  2. 2.Cardiologia PoliclinicoRomaItaly

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1991
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-85500-9
  • Online ISBN 978-3-642-85498-9
  • Buy this book on publisher's site